Viracta Therapeutics Future Growth
Future criteria checks 0/6
Viracta Therapeutics is forecast to grow earnings and revenue by 39.2% and 60.8% per annum respectively while EPS is expected to grow by 46.1% per annum.
Key information
39.2%
Earnings growth rate
46.1%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 60.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 17 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 45 | -68 | N/A | -11 | 3 |
12/31/2025 | 2 | -86 | N/A | -65 | 3 |
12/31/2024 | N/A | -62 | N/A | -48 | 4 |
12/31/2023 | N/A | -51 | -40 | -40 | N/A |
9/30/2023 | N/A | -48 | -38 | -38 | N/A |
6/30/2023 | N/A | -53 | -35 | -34 | N/A |
3/31/2023 | N/A | -51 | -35 | -35 | N/A |
12/31/2022 | N/A | -49 | -36 | -35 | N/A |
9/30/2022 | N/A | -50 | -35 | -35 | N/A |
6/30/2022 | N/A | -47 | -39 | -35 | N/A |
3/31/2022 | N/A | -46 | -37 | -33 | N/A |
12/31/2021 | N/A | -115 | -23 | -19 | N/A |
9/30/2021 | N/A | -110 | -20 | -16 | N/A |
6/30/2021 | N/A | -99 | -13 | -13 | N/A |
3/31/2021 | N/A | -94 | -10 | -10 | N/A |
12/31/2020 | N/A | -19 | -16 | -16 | N/A |
12/31/2019 | N/A | -14 | -10 | -10 | N/A |
12/31/2018 | 1 | -10 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VIRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VIRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VIRX is forecast to have no revenue next year.
High Growth Revenue: VIRX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VIRX's Return on Equity is forecast to be high in 3 years time